Universitaetsklinikum Mannheim GmbH
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Universitaetsklinikum Mannheim GmbH, cardiovascular research focuses on improving emergency care for acute myocardial infarction and testing whether faster self-treatment can help reduce the risk of repeat heart attacks.
- Evaluating a new option for people at risk of recurrent acute myocardial infarction
- Studying how early symptom-based treatment may improve outcomes in urgent cardiac care
This work aims to strengthen treatment effectiveness in time-sensitive heart disease and support better recovery after major cardiac events.
Hemic and Lymphatic Diseases
Research in hematologic diseases includes studies in essential thrombocythaemia, mature aggressive B-cell lymphoma, and other blood cancers, with a strong focus on improving disease control and immune recovery.
- Assessing new treatment approaches for essential thrombocythaemia
- Investigating therapy strategies for pediatric lymphoma and leukemia
- Exploring ways to improve outcomes after allogeneic hematopoietic cell transplantation
These trials are designed to refine treatment effectiveness, reduce complications, and support better long-term results in blood-related disorders.
Neoplasms
Oncology studies at this site cover several cancer types, including melanoma, endometrial carcinoma, colorectal cancer, breast cancer, and advanced laryngeal and hypopharyngeal squamous cell carcinoma.
- Testing immunotherapy to improve laryngectomy-free survival in advanced head and neck cancer
- Comparing treatments for resectable colon cancer and endometrial carcinoma
- Evaluating whether new approaches can improve recurrence-free survival in melanoma
- Studying combination therapies in metastatic breast cancer
Overall, the cancer portfolio at Universitaetsklinikum Mannheim GmbH is centered on testing innovative therapies that may improve survival, reduce recurrence, and support organ-preserving treatment.
Skin and Connective Tissue Diseases
Dermatology research includes atopic dermatitis studies that aim to improve symptom control, skin inflammation, and overall disease severity in adults and adolescents.
- Assessing whether a new therapy can better control moderate-to-severe atopic dermatitis
- Focusing on relief of signs, symptoms, and daily burden of chronic inflammatory skin disease
These trials are intended to expand treatment options for persistent skin conditions and improve quality of life for affected patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 18 therapeutic areas and 15 of 238 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 228 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 47 by active trials.
lock +46 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB11trials
lock +21 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Universitaetsklinikum Mannheim GmbH
lock Showing 1 of 137 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematopoietic cell transplantation complications | MaaT PHARMA | Phase II | Recruiting | Sep 2023 | — |
IMP list
lock Showing 1 of 238 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 14 | Unknown | 2018-09-11 | 2025-10-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.